 "Natco Pharma gets USFDA approval for leukemia drug")
Natco Pharma on Friday said it has received the USFDA approval to manufacture a drug for injections used in the treatement of chronic lymphocytic leukemia (CLL) and non-Hodgkins lymphoma.
"We are pleased to announce the final approval of Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (USFDA) for generic version of Bendamustine Hydrochloride powder for injection," Natco Pharma said in a BSE filing here.
Natco plans to launch this drug on November 1, 2019, or earlier, through its marketing partner Breckenridge Pharmaceutical Inc, in the US market, it said.
Currently, US-based Cephalon Inc sells Bendamustine Hydrochloride powder for injection under the brand name Treanda, which is indicated for the treatment of patients with CLL and non-Hodgkin's lymphoma.
Treanda had US sales of approximately $133 million for 12 months ending November 2016, according to IMS Health.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app